ArticleCancer biology & medicine2026
Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.
Jing Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.